Compare GDRX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDRX | EVO |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.1M | 994.5M |
| IPO Year | 2020 | N/A |
| Metric | GDRX | EVO |
|---|---|---|
| Price | $2.98 | $2.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $3.66 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.2M | 29.8K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $796,853,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $5.38 | $10.05 |
| P/E Ratio | $28.94 | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.77 | $2.31 |
| 52 Week High | $5.61 | $4.42 |
| Indicator | GDRX | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 64.75 | 57.27 |
| Support Level | $2.47 | $2.88 |
| Resistance Level | $3.12 | $3.30 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 85.94 | 91.89 |
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.